Fujifilm to develop large-scale cell culture manufacturing site in U.S.

By Nikita Chaurasia  | Date: 2021-01-08

Fujifilm to develop large-scale cell culture manufacturing site in U.S.

In a bid to proliferate its biopharmaceutical contract development and manufacturing business, Fujifilm Corporation is reportedly planning to invest around USD 2 billion (200 billion yen) towards the development of a large-scale cell culture manufacturing site in the United States.

A subsidiary of this Tokyo-based multinational conglomerate, FUJIFILM Diosynth Biotechnologies, which also has production facilities in Denmark, the United Kingdom, as well as the United States will operate the new facility, cited sources with relevant information.

The new manufacturing facility will reportedly offer large-scale cell culture production capabilities of bulk drug substances with 8 x 20,000L bioreactors, with a potential to grow and add 24 x 20,000L bioreactors as per the market demand. The facility will also offer automated assembly as well as packaging and labeling services. Sources confirmed that this new site is likely to begin operations by the spring of 2025.

According to the President of Fujifilm Corp. Kenji Sukeno, the fresh investments will allow the company to develop as well as manufacture new drugs which can cater to the unmet medical demands. He added that the company intends to promote human health while supporting the growth of the healthcare sector by employing its advanced technologies and facilities to offer a continuous supply of state-of-the-art biopharmaceuticals.

Meanwhile, Martin Meeson, CEO at FUJIFILM Diosynth Biotechnologies mentioned that the Japanese conglomerate will deploy its expertise in biopharmaceutical development as well as manufacturing for producing vaccines, gene therapies, recombinant proteins, and antibodies.

Fujifilm is focusing on expanding its end-to-end service offerings throughout its biopharmaceutical CDMO businesses, sources claimed. The company reportedly invested around USD 928 million in its Denmark site FUJIFILM Diosynth Biotechnologies' Hillerød, to boost its cell culture production capacities as well as to add commercial-scale drug manufacturing capabilities.

It is worth mentioning that Fujifilm intends to achieve a yearly revenue of USD 2 billion for its biopharmaceutical CDMO (contract development and manufacturing) business by March 2025. Reportedly, the company believes that the fresh investment will boost its bio CDMO business annual growth rate to 20%, exceeding market predictions.

Source Credits –

https://www.prnewswire.com/news-releases/fujifilm-to-invest-over-200-billion-yen-2-billion-usd-to-establish-new-large-scale-cell-culture-manufacturing-site-for-biopharmaceuticals-in-the-usa-301202418.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

Pacific Island pushes Japan to delay wastewater release from Fukushima

Pacific Island pushes Japan to delay wastewater release from Fukushima

By Nikita Chaurasia

Pacific Island nations have reportedly pushed Japan to postpone the release of Fukushima nuclear power plant wastewater due to concerns that it may pollute fishing grounds. An appeal was made on Wednesday when Japan announced that treated sewage f...

Activist groups take Danone to court over excessive use of plastics

Activist groups take Danone to court over excessive use of plastics

By Nikita Chaurasia

Danone, the French bottled water and yogurt firm, is reportedly being sued in court by three environmental activists’ groups for failing to cut its plastic footprint significantly. According to the groups, the maker of Evian and Volvic miner...

Bosch expands security with dashcams designed for rideshare drivers

Bosch expands security with dashcams designed for rideshare drivers

By Nikita Chaurasia

Bosch, the German technology company, has reportedly expanded its security footprint in the ridesharing market with the launch of its latest security dashcams. At CES 2023, Las Vegas, the German tech firm unveiled a new integrated smart camera on ...

Australia: PM Albanese denies potential $450M payout to Rio Tinto

Australia: PM Albanese denies potential $450M payout to Rio Tinto

By Nikita Chaurasia

Australia's Prime Minister Anthony Albanese has reportedly denied rumors that Rio Tinto and its partners could receive a $450 million settlement for the Gladstone power station, which would bring the total compensation for the coal price limit to...

UK: Firms still struggle with post-Brexit trading and red tape

UK: Firms still struggle with post-Brexit trading and red tape

By Nikita Chaurasia

Businesses in the UK are still reportedly grappling after two years following the beginning of post-Brexit trading, as suggested by a new report. According to the British Chambers of Commerce (BCC), firms are still battling increased red tape and ...